Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

January 6, 2003

Briefing Information

COZAAR™ (losartan potassium)


The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Losartan Potassium - LIFE Study, Merck Research Laboratories (PDF)

Cozaar™ Clinical Review, FDA. (HTM) (PDF) (Word)

Cozaar™ Clinical Review Errata (HTM) (PDF) (Word)

Cozaar™ Statistical Review, FDA (HTM) (PDF) (Word)